Stella Pharma Corporation (4888.T)
JPY 555.0
(0.18%)
JPY 555.0
(0.18%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 217.29 Million JPY | 5.0% |
| 2022 | 206.94 Million JPY | 143.87% |
| 2021 | 84.85 Million JPY | -53.32% |
| 2020 | 181.77 Million JPY | 725.85% |
| 2019 | -29.04 Million JPY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 43.03 Million JPY | -21.21% |
| 2023 Q2 | 68.76 Million JPY | 26.62% |
| 2023 FY | 217.29 Million JPY | 5.0% |
| 2023 Q4 | 54.61 Million JPY | 37.89% |
| 2023 Q3 | 39.6 Million JPY | -42.4% |
| 2023 Q1 | 54.3 Million JPY | 14.07% |
| 2022 Q3 | 64.36 Million JPY | 76.6% |
| 2022 FY | 206.94 Million JPY | 143.87% |
| 2022 Q4 | 47.6 Million JPY | -26.03% |
| 2022 Q2 | 36.44 Million JPY | 0.0% |
| 2021 FY | 84.85 Million JPY | -53.32% |
| 2020 FY | 181.77 Million JPY | 725.85% |
| 2019 FY | -29.04 Million JPY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.88 Billion JPY | 88.45% |
| PRISM BioLab Co.,LTD | 80.3 Million JPY | -170.588% |
| GNI Group Ltd. | 22.43 Billion JPY | 99.031% |
| Linical Co., Ltd. | 3.77 Billion JPY | 94.249% |
| Trans Genic Inc. | 2.24 Billion JPY | 90.339% |
| MEDINET Co., Ltd. | 98.25 Million JPY | -121.164% |
| Soiken Holdings Inc. | 2.48 Billion JPY | 91.246% |
| Cytori Cell Research Institute, Inc. | 1.29 Billion JPY | 83.189% |
| AnGes, Inc. | -3.06 Billion JPY | 107.089% |
| OncoTherapy Science, Inc. | -177.71 Million JPY | 222.271% |
| Nxera Pharma Co., Ltd. | 9.66 Billion JPY | 97.751% |
| Immuno-Biological Laboratories Co., Ltd. | 517.29 Million JPY | 57.993% |
| NanoCarrier Co., Ltd. | 110.95 Million JPY | -95.842% |
| Carna Biosciences, Inc. | 1.45 Billion JPY | 85.02% |
| CanBas Co., Ltd. | -984 Million JPY | 122.083% |
| D. Western Therapeutics Institute, Inc. | 391.69 Million JPY | 44.524% |
| RaQualia Pharma Inc. | 1.65 Billion JPY | 86.879% |
| Chiome Bioscience Inc. | 398.59 Million JPY | 45.484% |
| Kidswell Bio Corporation | 1.03 Billion JPY | 79.094% |
| PeptiDream Inc. | 17.21 Billion JPY | 98.738% |
| Oncolys BioPharma Inc. | 30.6 Million JPY | -610.008% |
| Ribomic Inc. | -10.5 Million JPY | 2169.111% |
| SanBio Company Limited | -14.5 Million JPY | 1598.194% |
| Healios K.K. | 108 Million JPY | -101.202% |
| BrightPath Biotherapeutics Co., Ltd. | -341 Thousand JPY | 63823.754% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -59.04 Million JPY | 468.015% |
| Delta-Fly Pharma, Inc. | -1.51 Million JPY | 14471.561% |
| StemRIM | -44.34 Million JPY | 589.973% |
| CellSource Co., Ltd. | 3.18 Billion JPY | 93.177% |
| FunPep Company Limited | -680.28 Million JPY | 131.942% |
| Kringle Pharma, Inc. | 69.25 Million JPY | -213.788% |
| TMS Co., Ltd. | -6.95 Million JPY | 3226.59% |
| Noile-Immune Biotech Inc. | 314.56 Million JPY | 30.92% |
| Cuorips Inc. | 9.63 Million JPY | -2156.235% |
| K Pharma,Inc. | 910 Million JPY | 76.121% |
| Takara Bio Inc. | 25.45 Billion JPY | 99.146% |
| ReproCELL Incorporated | 1.1 Billion JPY | 80.33% |
| PhoenixBio Co., Ltd. | 1.19 Billion JPY | 81.817% |
| StemCell Institute Inc. | 1.57 Billion JPY | 86.211% |
| Japan Tissue Engineering Co., Ltd. | 1.66 Billion JPY | 86.963% |
| CellSeed Inc. | 107.15 Million JPY | -102.788% |